Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTBB3 Follow-up
2024-517925-25-00Phase 2Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxytocin in Prader-Willi syndrome (PWS) (2 cohorts), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoints: Adverse events and serious adverse events, Occurrence of main comorbidities and 1 more. Started Dec 2024; status: completed.
02
Drugs
oxytocin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2024-517925-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517925-25-00.